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Abstract
The risk of chronic obstructive pulmonary disease (COPD), as well as thyroid diseases increases with age. COPD is a common 
systemic disease associated with chronic inflammation. Many endocrinological disorders, including thyroid gland diseases are 
related to systemic inflammation. Epidemiological studies suggest that patients with COPD are at higher risk of thyroid disorders. 
These associations are not well-studied and thyroid gland diseases are not included on the broadly acknowledged list of COPD 
comorbidities. They may seriously handicap quality of life of COPD patients. Unfortunately, the diagnosis may be difficult, as many 
signs are masked by the symptoms of the index disease. The comprehension of the correlation between thyroid gland disorders 
and COPD may contribute to better care of patients. In this review, we attempt to revise available literature describing existing 
links between COPD and thyroid diseases.
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Introduction
Chronic obstructive pulmonary disease 
(COPD) is a leading cause of morbidity and mor-
tality worldwide [1]. The risk increases suddenly 
with age, and the peak incidence falls when pa-
tients are over 60 [1]. It has been acknowledged 
that chronic inflammation occurring in COPD is 
systemic in nature, but it occurs primarily in the 
lung, from where inflammatory cytokines “spill 
over” and inflammation spreads to other organs 
of the body [1–3]. Systemic inflammation may 
be driven by the main risk factor — cigarette 
smoking, and it persists after smoking cessation 
[1, 3, 4]. The inflammation has an impact on other 
systems, for example: cardiovascular, skeletal 
muscles, skeleton, brain etc. [3–5]. According 
to GOLD (Global Initiative for Obstructive Lung 
Disease), many comorbidities like coronary artery 
disease, diabetes and metabolic syndrome, de-
pression, cachexia, osteoporosis are undoubtedly 
associated with COPD by their frequent co-occur-
rence [1]. The link between other chronic diseases 
and COPD may not be so obvious, but some data 
suggest many underrecognized associations [5]. 
COPD interferes with endocrinological homoeo-
stasis not only by means of systemic inflammation 
[6]. Other factors like neurohormones, blood gas 
abnormalities, glucocorticoid administration also 
disturb hormonal balance [6]. On the other hand, 
hormones may affect regulation of breathing [7]. 
Some hormones act on the level of the central ner-
vous system, some have an impact on peripheral 
chemoreceptors, others may contribute to this 
process by influencing the metabolism rate, and 
others exert their effect directly on receptors in 
the respiratory tract [7]. Drugs frequently used 
by COPD patients to treat comorbidities, such as 
amiodarone [8], lithium carbonate [9] or potas-
sium iodine [10] may lead to hypothyroidism. 
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On the other hand, there are known cases of 
thyrotoxicosis induced by iodinated glycerol [11], 
amiodarone [12] or lithium salts [9]. 
There is a growing evidence that thyroid gland 
function may be disturbed in COPD patients [2, 5, 
13–16]. Some studies show that thyroid diseases 
are more frequent among patients with COPD. In 
a big population-based study performed in the city 
of Madrid, Spain, it was shown that the prevalence 
of a thyroid disease was higher in COPD patients 
(14.21%) than the expected standardized prevalence 
of chronic diseases (11.06%) [5]. The general occur-
rence of thyroid disorders is estimated at 14–20% 
among stable COPD patients [5, 17] and at 70% 
during an exacerbation [17]. The thyroid diseases 
occur more frequently among women than men with 
COPD [5], the same as in the general population [18]. 
The aim of this review is to discuss the ava-
ilable data on the coexistence of thyroid gland 
disorders in COPD.
Search methodology
The initial search was conducted using 
PubMed with the subject headings “pulmonary 
disease, chronic obstructive pulmonary disease” 
and “endocrinological disorders” or “endocrino-
logy”. All abstracts were assessed for relevance, 
and articles of the relevant studies were retrie-
ved. Subsequent searches utilized the following 
combinations of subject headings on PubMed: 
“CODP & thyroid hormones” or “COPD & thyroid 
disorders” or “COPD & hypothyrodism” or “COPD 
& hyperthyrodism” or “COPD & non-thyroidal ill-
ness syndrome”. For relevant titles, the abstracts 
were reviewed and, if still relevant, the article in 
full version was retrieved. References within the 
selected articles were also reviewed in terms of 
their relevance. Table 1 shows a number of hits 
and final selection from each thematic area. Ac-
cording to PRISMA guidelines, this review should 
be classified as a narrative systematic review [19].
Chronic inflammation as a possible link between 
COPD and thyroid gland diseases
Chronic inflammation in COPD is associated 
with production of interleukin (IL)-1b, tumor ne-
crosis factor (TNF)-a, IL-8, IL-6, and fibrinogen 
by alveolar macrophages and neutrophils [20]. 
In humans, intravenous administration of re-
combinant IL-6 resulted in acute reduction of 
triiodothyronine (T3) and thyroid stimulating 
hormone (TSH) levels [21]. Karadag et al. assessed 
thyroid hormones and both serum IL-6 and TNF-a 
during exacerbation period, recovery and stable 
phase of COPD. As expected, cytokine levels were 
higher in patients with COPD (both stable and 
exacerbated), compared to age and sex — adjusted 
control group [17]. The authors found a positive 
correlation between IL-6 and total triiodothyro-
nine (TT3) and TT3/TT4 in stable patients [17]. 
Tobacco smoke contains considerable amo-
unts of free radicals that may damage the struc-
ture of the respiratory tract and promote inflam-
mation [1, 22]. Cigarette smoke attracts activated 
inflammatory cells to the lungs - another source 
of free radicals and oxidants contributing to su-
stained inflammation [23]. Also the endocrine 
system is not inert to the components of cigarette 
smoke [24–26]. Higher levels of serum total triio-
dothyronine (TT3) were found in young healthy 
smokers comparing to non-smoking control sub-
jects [25], what may suggest that smoking acts 
independently of coexistent diagnosis of COPD. 
Figure 1 presents possible links between tobacco 
smoking, chronic inflammation, systemic nature 
of COPD, and thyroid dysfunction. 
Hypothyroidism
The prevalence of hypothyroidism in the 
general population is 0.9% among men and 4.8% 
among women [27]. Its frequency increases with 
age [18]. Some studies have shown the relation-
ship between thyroid hormone levels and blood 
gas parameters [2]. Terzano et al. [2] described 
lower blood oxygen pressure (pO2) in patients 
with overt hypothyroidism, compared to other 
groups consisting of patients with subclinical hy-
pothyroidism, normal subjects and patients with 
hyperthyroidism. Moreover, in the same research, 
the authors observed significant increase of the 
blood carbon dioxide pressure (pCO2) levels in 
patients with hypothyroidism, although a correla-
tion between TSH and pCO2 was not present [2]. 
Dimopoulou et al. reported strong positive 
correlation between serum total triiodothyronine/
total thyroxine (TT3/TT4) ratio and arterial oxy-
gen pressure (PaO2), but only in COPD patients 
with FEV1 <50% predicted value, and not in 
those above this threshold [28]. This observation 
suggests the relationship between low conversion 
rate of T4 to T3 in peripheral tissues and hypox-
emia in most severe COPD patients [29]. In anoth-
er study, it was demonstrated that obstruction se-
verity is associated with reduced basal and stim-
ulated thyroid stimulating hormone (TSH) [30]. 
However, the exact mechanism of the above con-
nection is not known.
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Table 1. The process of Pubmed search in selected areas
Search area Combination of PubMed  
terms “COPD” and:
PubMed search Abstract selection The most relevant  
for the topic
Endocrinological 
Disorders
Endocrinological 
Disorders
Endocrinology
14
95
12
34
3
10
Thyroid Thyroid 146 24 5
Thyroid disorders 156 50 21
Hypothyrodism 81 27 18
Hiperthyrodism 43 14 5
Non-thyroidal ilness syndrome 2 2 2
Figure 1. Possible links between chronic obstructive pulmonary dise-
ase, cigarette smoking and thyroid gland disorders
Muscle weakness is one of the symptoms 
of hypothyroidism [2, 31]. The deterioration of 
main respiratory muscle function [32] aggravates 
already weakened ventilation in patients with 
COPD [2]. Some adapting mechanisms in COPD 
patients have been described, like shortening of 
the length of sarcomeres and an increase in the 
concentration of mitochondria [32]. The muscle 
weakness may manifest in worse spirometry 
results [2]. In hypothyroidism mean inspiratory 
pressure (MIP) and mean expiratory pressure 
(MEP) are decreased [2, 31], supposedly due to de-
creased respiratory muscle strength [33]. The as-
sociation of free T3 (fT3) level with arterial blood 
gases and pulmonary function parameters (vital 
capacity [VC] or forced vital capacity [FVC], FEV1, 
peak expiratory flow [PEF]) has been demon-
strated [14]. Another study also confirmed lower 
values of MEP in COPD patients with hypothy-
roidism than in those without this condition [31]. 
The authors observed significantly lower values of 
FVC, FEV1/FVC, forced expiratory flow at 25 and 
75% (FEF25-75%) in this group of patients [31]. 
Others reported on correlation between MEP and 
MIP values and thyroid function [2]. Interestingly, 
there is also a positive correlation between TSH 
values and acute exacerbations frequency [31]. 
Among the patients with hypothyroidism, the 
exacerbations occurred more frequently than in 
patients without hypothyroidism, and TSH value 
turned out to be the only significant determinant 
of exacerbation frequency [31]. Further studies 
are needed to verify if impaired thyroid function 
really increases the risk of COPD exacerbation 
and if proper hormonal treatment would impact 
the clinical outcome. Authors of other studies re-
ported on lower spirometry parameters in patients 
without clinically diagnosed hypothyroidism, but 
with low values of thyroid hormones, that still re-
mained within normal limits [14]. It is of note that 
the muscle weakness, caused by hypothyroidism, 
is reversible after treatment [33]. 
Thyroid dysfunction, defined by the use of 
thyroid function tests (TFT), was demonstrated in 
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more than half of COPD patients with respiratory 
failure (52.3%) and in slightly lower percentage 
of patients without this condition (44.4%) [34], 
however, the difference between the groups was 
not statistically significant. Moreover, patients 
with both low levels of fT3 and free T4 (fT4) 
needed invasive mechanical ventilation more 
often than those from the group with normal TFT 
scores [34]. The authors also observed the higher 
rate of in-hospital mortality among patients with 
low levels of either fT3 or fT4 [34]. Significant dif-
ference of TSH level between groups of patients 
with COPD exacerbation and healthy subjects 
was demonstrated [34]. Lower fT3 in the course 
of COPD exacerbation was also confirmed by 
other authors [16]. The authors also found that 
fT3 negatively correlated with bicarbonate levels 
and fT4, also negatively, with hemoglobin [16].
Hyperthyroidism
Hyperthyroidism occurs in the general popu-
lation with a frequency of 2.5% in women and 
0.6% in men [27]. One study assessed a preva-
lence of subclinical hyperthyroidism among a 
group of 34 men with COPD, and estimated the 
rate at 20.6%, however, the examined group was 
too small to extrapolate the results to entire po-
pulation of COPD patients [24]. Further studies 
to verify these results are needed. 
The hyperthyroidism itself may influence 
pattern of breathing, probably due to the action of 
thyroid hormones on central (increased hypoxic 
drive) and peripheral (hypercapnic drive) regula-
tory mechanisms. Dyspnea and hyperventilation 
are frequent in patients with hyperthyroidism, 
and may lead to relatively higher levels of pO2 and 
lower levels of pCO2 [2, 7]. In patients with COPD 
and hyperthyroidism, muscle weakness may also 
appear, and may result from increased catabolism 
[33, 35]. The loss of muscle mass and muscle 
strength in patients with thyrotoxicosis has been 
confirmed [36]. Similarly to hypothyroidism, loss 
of muscle mass may be responsible for decreased 
lung function. Siafacas et al. [35] confirmed de-
creased FEV1, FVC, VC, MEP and MIP in hyper-
thyroid patients, compared to euthyroid subjects 
(COPD patients were excluded from the study). 
All these parameters improved significantly after 
treatment, with the exception of FEV1/FVC ratio 
[35]. MEP and MIP were measured to define glo-
bal respiratory muscle strength [35]. Both of the 
above values were reduced, compared to results 
of the control group, and they also increased after 
treatment of hyperthyroidism [35]. Similar results 
were obtained in another study, where MEP and 
MIP also increased significantly after treatment 
of hyperthyroidism [37]. A significant correlation 
was reported between T3, T4 levels and MEP 
and MIP [35]. There was no association between 
maximal expiratory and inspiratory pressures and 
TSH [35]. The muscles wasting phenomenon may 
also result from malnutrition, which is common 
in patients with COPD [38, 39]. Regardless of 
the reason, muscle weakness may be a cause of 
respiratory failure, therefore it may be of special 
importance to diagnose and treat hyperthyroidism 
as a reversible factor in respiratory failure [40]. 
Uzun et al. have demonstrated higher pro-
portion of patients with low TSH in severe COPD 
patients compared to healthy control group, 
although the mean values of TSH, fT3 and fT4 
were not significantly different between groups 
[15]. Similarly, Dimopoulou et al. did not find 
significant difference in mean levels of TSH, fT3 
and fT4 between mild to moderate COPD patients 
and control group, however the authors found 
strong negative correlation between TT3/TT4 
ratio and pO2 in the sub-group of the most severe 
COPD patients [28]. This finding was confirmed 
by Hussein et al. [41], who found higher levels 
of fT3 in COPD group and significant negative 
correlations between fT3 levels and both PaO2 and 
saturation of hemoglobin with oxygen (SatO2), 
and pulmonary function tests results of COPD 
patients. Severity of COPD increased significantly 
with growing fT3. The authors suggested that fT3 
may be a marker of systemic impact of COPD [41]. 
The authors also reported on the positive correla-
tion between fT3 and PaCO2 [41], thus confirming 
earlier results of another group of authors [14]. 
This observation is somewhat unexpected, as the 
tendency to hyperventilation and hypocapnia 
was rather reported in non-COPD thyreotoxic 
patients [2, 7]. This may reflect the alveolar hy-
poventilation present in COPD patients, which 
enables “washing out” the excess of CO2 from 
the alveoli. In contrast to Hussein’s results, Gow 
et al. [42] did not find significant differences in 
thyroid hormones levels between COPD and non-
COPD elderly patients. In this study, delayed and 
reduced TSH responses to thyrotropin releasing 
hormone (TRH) also occurred in both groups, in-
dicating that the changes in the hypothalamic-pi-
tuitary-thyroid axis were not specific to hypoxic 
patients. Reduced responses have been described 
as an age related effect, particularly in men, whe-
reas delayed responses were thought to indicate 
hypothalamic damage. Absence of TSH response 
to TRH occurred only in patients with COPD but 
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this has been described in elderly patients with 
various acute illnesses. The severe illness and 
possible malnourishment of COPD patients are 
likely to have had an additional suppressive effect 
on the TSH response to TRH [42].
Hypermetabolism in COPD
Hypermetabolism is common among pa-
tients with COPD [43]. Coenzyme Q10 [CoQ10] 
is used to characterize the metabolic status in 
patients suffering from thyroid disorders [44]. 
It was shown that CoQ10 and thyroid hormones 
are inversely correlated [44]. The level of CoQ10 
in hypothyroidism (even in subclinical cases) 
is elevated [36], while CoQ10 level in patients 
with hyperthyroidism is reduced [44]. In the 
cited study, significantly higher values of CoQ10 
in a group of COPD patients with low fT3 levels 
were observed, compared to COPD patients with 
normal fT3 levels [44]. Similar results were noted, 
comparing these two groups in respect to CoQ10/
cholesterol ratio. Again, the COPD group with low 
fT3 showed higher levels of this ratio than COPD 
group with normal fT3 [44]. 
The weight control in patients with COPD is 
an important issue. Hypermetabolism in hyper-
thyroidism and hypometabolism in hypothyro-
idism may complicate the treatment of patients 
with chronic diseases. Therefore, further resear-
ches on the utility of the above index are neces-
sary because they can provide information about 
the level of metabolism. Together with incorrect 
dietary intake, it may lead to weight loss. Intere-
stingly, the occurrence of thyroid dysfunction has 
not been evaluated for its influence on cachexia 
in patients with COPD so far [43]. 
Non-thyroidal illness syndrome
Non-thyroidal illness syndrome (NTIS) may 
be defined as reduced conversion of T4 to T3 in 
different acute and chronic systemic disorders. 
NTIS occurs more frequently than hypothyro-
idism and subclinical hypothyroidism [16]. This 
clinical entity is characterized by a decreased 
TT3 and fT3, normal or decreased TT4 and fT4, 
and unchanged TSH levels [17]. The mechanisms 
leading to NTIS are largely unknown and further 
studies in this field are required [16]. Karadag et 
al. [17] evaluated 103 moderate-to-severe COPD 
patients and 30 controls with normal pulmonary 
function. The COPD group was further divided 
into patients with stable disease and with acute 
exacerbation. The study showed that TT3 and 
fT3 levels and TT3/TT4 ratio were lower in the 
COPD group than in controls, and the differen-
ce was more significant for fT3. Besides, TSH, 
TT3, fT3 levels and TT3/TT4 ratio were lower in 
the exacerbation group in comparison with the 
stable COPD group. In addition, serum TT3 and 
TT3/TT4 ratio were lower in severe, compared 
to moderate COPD. Moreover, in patients with 
exacerbation, TSH, TT3, fT3 levels and TT3/TT4 
ratio increased in follow-up measurements on the 
day of discharge from hospital and one month 
later. The hormonal changes during follow-up 
after COPD exacerbation followed normalization 
of PaO2 and PaCO2 during recovery. The increase 
of TSH levels following improvement of hypoxia 
and stabilization of clinical condition denotes 
delayed pituitary response to TRH, which was 
earlier impaired by hypoxia [17]. On the contrary, 
Gow et al. [42] did not find any correlation be-
tween arterial blood gases and thyroid hormones, 
and therefore suggested that aging and illness per 
se might be more important factors leading to 
thyroid dysfunction than hypoxemia. Serum TT3, 
fT3 and TT3/TT4, which decrease with age and in 
COPD exacerbations as shown in the cited study, 
indicate decreased metabolic clearance of T4 
and decreased peripheral conversion to T3. This 
inverse correlation suggests that aging may also 
play a role in thyroid dysfunction in addition to 
hypoxemia [16]. According to foregoing findings, 
thyroid disease should not be recognized during 
COPD exacerbation because of alternations in thy-
roid hormones related to severe clinical condition 
and not to true thyroid disease [17]. In another 
study, it was shown, that NTIS may be regarded 
as independent predictor of prolonged weaning 
in intubated COPD patients [45]. Importantly, 
prolonged weaning is associated with increased 
mortality and morbidity in the intensive care unit 
[45]. Presumably, NTIS (especially low fT3) may 
reflect severity of inflammation, hypoxia or other 
pathological processes associated with COPD 
exacerbation [45]. Furthermore, the authors pro-
posed to add baseline thyroid function tests to the 
predictive capacity of the APACHE II score [45]. 
The authors also reported on successful weaning 
from mechanical ventilation (MV) after proper 
hormonal supplementation in patients with new-
ly diagnosed hypothyroidism [45]. Although the 
authors noticed that further studies are necessary 
to assess the significance of thyroid hormones 
supplementation in patients with NTIS [45].
It should be remembered that various factors 
can affect thyroid function by stimulating or sup-
pressing it [17, 45]. More frequent occurrence of 
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pulmonary infections among patients with NTIS 
has been demonstrated [45]. Some cytokines 
and immune system cells restrain thyroid gland 
activity [45]. Therefore, treatment of pulmonary 
infections or any infection, becomes an important 
aim to reach. 
Conclusions
The signs or symptoms of thyroid disorders 
may be non-specific, especially among the elder-
ly, therefore the differential diagnosis between 
symptoms of COPD and symptoms related to 
thyroid disease can cause difficulties. Many data 
show higher risk of thyroid hormones alterations 
(both hyper or hypothyroidism) in COPD patients. 
Both hyperthyroidism and hypothyroidism may 
influence respiration by different mechanisms, 
even in subjects with intact respiratory system. 
Therefore it is hard to distinguish whether hor-
monal changes are the reason or a consequence of 
different respiratory signs and symptoms. In some 
instances the correction of hormonal alternations 
may improve the quality of life of COPD patients 
and other disease outcomes. The comprehension of 
an association between COPD, thyroid gland func-
tion and thyroid disorders may provide important 
information about the systemic nature of COPD. 
Conflict of interest
The authors declare no conflict of interest.
Acknowledgements 
The authors are supported by the Healthy 
Ageing Research Centre project (REGPOT-2012- 
-2013-1, 7FP).
References
1. Gómez F, Rodriguez-Roisin R. Global Initiative for Chronic Obs-
tructive Lung Disease (GOLD) guidelines for chronic obstructive 
pulmonary disease. Current Opinion in Pulmonary Medicine. 
2002; 8(2): 81–86, doi: 10.1097/00063198-200203000-00001.
2. Terzano C, Romani S, Paone G, et al. COPD and thyroid dys-
functions. Lung. 2014; 192(1): 103–109, doi: 10.1007/s00408-
013-9537-6, indexed in Pubmed: 24281671.
3. Fabbri LM, Luppi F, Beghé B, et al. Complex chronic comor-
bidities of COPD. Eur Respir J. 2008; 31(1): 204–212, doi: 
10.1183/09031936.00114307, indexed in Pubmed: 18166598.
4. van der Molen T. Co-morbidities of COPD in primary care: 
frequency, relation to COPD, and treatment consequen-
ces. Prim Care Respir J. 2010; 19(4): 326–334, doi: 10.4104/
pcrj.2010.00053, indexed in Pubmed: 20842323.
5. García-Olmos L, Alberquilla A, Ayala V, et al. Comorbidity in 
patients with chronic obstructive pulmonary disease in family 
practice: a cross sectional study. BMC Fam Pract. 2013; 14: 11, 
doi: 10.1186/1471-2296-14-11, indexed in Pubmed: 23324308.
6. Doehner W, Haeusler KG, Endres M, Anker SD, MacNee W, 
Lainscak M. Neurological and endocrinological disorders: or-
phans in chronic obstructive pulmonary disease. Respir Med. 
2011; 105 Suppl 1: S12–19. doi: http://dx.doi.org/10.1016/
S0954-6111(11)70005-1
7. Saaresranta T, Polo O. Hormones and Breathing. Chest. 2002; 
122(6): 2165–2182, doi: 10.1378/chest.122.6.2165.
8. Różycka-Kosmalska M, Michalak R, Kosmalski M, et al. 
[Clinical procedure in amiodarone-induced thyroid dys-
function]. Pol Merkur Lekarski. 2016; 40(235): 46–52, 
doi: 10.1002/9781118849897.ch20, indexed in Pubmed: 
26891437.
9. Siyam FF, Deshmukh S, Garcia-Touza M. Lithium-associated 
hyperthyroidism. Hosp Pract (1995). 2013; 41(3): 101–104, 
doi: 10.3810/hp.2013.08.1073, indexed in Pubmed: 23948626.
10. Jubiz W, Carlile S, Lagerquist LD. Serum thyrotropin and thy-
roid hormone levels in humans receiving chronic potassium 
iodide. J Clin Endocrinol Metab. 1977; 44(2): 379–382, doi: 
10.1210/jcem-44-2-379, indexed in Pubmed: 838843.
11. Becker CB, Gordon JM. Iodinated glycerol and thyroid dys-
function. Four cases and a review of the literature. Chest. 
1993; 103(1): 188–192, doi: 10.1378/chest.103.1.188, indexed 
in Pubmed: 8417876.
12. Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyro-
id. 2001; 11(5): 493–500, doi: 10.1089/105072501300176453, 
indexed in Pubmed: 11396708.
13. Laghi F, Adiguzel N, Tobin MJ. Endocrinological deran-
gements in COPD. Eur Respir J. 2009; 34(4): 975–996, doi: 
10.1183/09031936.00103708, indexed in Pubmed: 19797671.
14. Okutan O, Kartaloglu Z, Onde ME, et al. Pulmonary function tests 
and thyroid hormone concentrations in patients with chronic ob-
structive pulmonary disease. Med Princ Pract. 2004; 13(3): 126–
–128, doi: 10.1159/000076950, indexed in Pubmed: 15073423.
15. Uzun K, Atalay H, Inal A. Thyroid hormon levels in patients 
with acute exacerbation of chronic obstructive pulmonary 
disease. Eur J Gen Med. 2007; 4: 80–82.
16. Gupta M, Vardey S, Joshi N, et al. Evaluation of thyroid dys-
function in chronic obstructive pulmonary disease. Biomed 
Res. 2013; 24: 110–113.
17. Karadag F, Ozcan H, Karul AB, et al. Correlates of non-thyro-
idal illness syndrome in chronic obstructive pulmonary di-
sease. Respir Med. 2007; 101(7): 1439–1446, doi: 10.1016/j.
rmed.2007.01.016, indexed in Pubmed: 17346957.
18. Morganti S, Ceda GP, Saccani M, et al. Thyroid disease in 
the elderly: sex-related differences in clinical expression. J 
Endocrinol Invest. 2005; 28(11 Suppl Proceedings): 101–104, 
indexed in Pubmed: 16760635.
19. Panic N, Leoncini E, de Belvis G, et al. Evaluation of the 
endorsement of the preferred reporting items for systematic 
reviews and meta-analysis (PRISMA) statement on the quality 
of published systematic review and meta-analyses. PLoS ONE. 
2013; 8(12): e83138, doi: 10.1371/journal.pone.0083138, in-
dexed in Pubmed: 24386151.
20. Korytina GF, Akhmadishina LZ, Kochetova OV, et al. Inflamma-
tory and Immune Response Genes Polymorphisms are Associa-
ted with Susceptibility to Chronic Obstructive Pulmonary Di-
sease in Tatars Population from Russia. Biochem Genet. 2016; 
54(4): 388–412, doi: 10.1007/s10528-016-9726-0, indexed in 
Pubmed: 27003425.
21. Stouthard JM, van der Poll T, Endert E, et al. Effects of acute 
and chronic interleukin-6 administration on thyroid hormone 
metabolism in humans. J Clin Endocrinol Metab. 1994; 79(5): 
1342–1346, doi: 10.1210/jcem.79.5.7962327, indexed in Pub-
med: 7962327.
22. Sanguinetti CM. N-acetylcysteine in COPD: why, how, and 
when? Multidiscip Respir Med. 2015; 11: 8, doi: 10.1186/
s40248-016-0039-2, indexed in Pubmed: 26855777.
23. McCusker K. Mechanisms of respiratory tissue injury from 
cigarette smoking. Am J Med. 1992; 93(1A): 18S–21S, doi: 
10.1016/0002-9343(92)90622-i, indexed in Pubmed: 1496999.
24. Agin K, Namavary J. A Survey on Thyroid Hormonal Status 
among Moderate to Severe Stable Chronic Obstructive Pulmo-
nary Disease. Int J Med Toxicol Forensic Med 2013; 3: 106–113.
25. Meral I, Arslan A, Him A, et al. Smoking-related Alterations in 
Serum Levels of Thyroid Hormones and Insulin in Female and 
Male Students. Altern Ther Health Med. 2015; 21(5): 24–29, 
doi: 10.1530/endoabs.37.ep878, indexed in Pubmed: 26393988.
Advances in Respiratory Medicine 2017, vol. 85, no. 1, pages 28–34 
34 www.journals.viamedica.pl
26. Leach PT, Gould TJ. Thyroid hormone signaling: Contribution 
to neural function, cognition, and relationship to nicotine. 
Neurosci Biobehav Rev. 2015; 57: 252–263, doi: 10.1016/j.
neubiorev.2015.09.001, indexed in Pubmed: 26344666.
27. Bjoro T, Holmen J, Krüger O, et al. Prevalence of thyroid dise-
ase, thyroid dysfunction and thyroid peroxidase antibodies in 
a large, unselected population. The Health Study of Nord-Tron-
delag (HUNT). Eur J Endocrinol. 2000; 143(5): 639–647, doi: 
10.1530/eje.0.1430639, indexed in Pubmed: 11078988.
28. Dimopoulou I, Ilias I, Mastorakos G, et al. Effects of severity 
of chronic obstructive pulmonary disease on thyroid func-
tion. Metab Clin Exp. 2001; 50(12): 1397–1401, doi: 10.1053/
meta.2001.28157, indexed in Pubmed: 11735083.
29. Mortoglou A, Candiloros H. The serum triiodothyronine to 
thyroxine (T3/T4) ratio in various thyroid disorders and after 
Levothyroxine replacement therapy. Hormones (Athens). 2004; 
3(2): 120–126, doi: 10.14310/horm.2002.11120, indexed in 
Pubmed: 16982586.
30. Bratel T, Wennlund A, Carlström K. Impact of hypoxaemia on 
neuroendocrine function and catecholamine secretion in chro-
nic obstructive pulmonary disease (COPD). Effects of long-
term oxygen treatment. Respir Med. 2000; 94(12): 1221–1228, 
doi: 10.1053/rmed.2000.0953, indexed in Pubmed: 11192959.
31. Sarinc Ulasli S, Bozbas SS, Ozen ZE, et al. Effect of thyroid 
function on COPD exacerbation frequency: a preliminary stu-
dy. Multidiscip Respir Med. 2013; 8(1): 64, doi: 10.1186/2049-
6958-8-64, indexed in Pubmed: 24079533.
32. Orozco-Levi M, Gea J, Lloreta JL, et al. Subcellular ada-
ptation of the human diaphragm in chronic obstructive 
pulmonary disease. Eur Respir J. 1999; 13(2): 371–378, 
doi: 10.1183/09031936.99.13237199, indexed in Pubmed: 
10065684.
33. Siafakas NM, Salesiotou V, Filaditaki V, et al. Respiratory musc-
le strength in hypothyroidism. Chest. 1992; 102(1): 189–194, 
doi: 10.1378/chest.102.1.189, indexed in Pubmed: 1623751.
34. Bacakoğlu F, Başoğlu OK, Gürgün A, et al. Can impairments of 
thyroid function test affect prognosis in patients with respira-
tory failure? Tuberk Toraks. 2007; 55(4): 329–335, indexed in 
Pubmed: 18224499.
35. Siafakas NM, Milona I, Salesiotou V, et al. Respiratory musc-
le strength in hyperthyroidism before and after treatment. 
Am Rev Respir Dis. 1992; 146(4): 1025–1029, doi: 10.1164/
ajrccm/146.4.1025, indexed in Pubmed: 1416391.
36. Stein M, Kimbel P, Johnson RL. PULMONARY FUNCTION IN 
HYPERTHYROIDISM. J Clin Invest. 1961; 40(2): 348–363, doi: 
10.1172/JCI104262, indexed in Pubmed: 16695851.
37. Pino-García JM, García-Río F, Díez JJ, et al. Regulation of 
breathing in hyperthyroidism: relationship to hormonal and 
metabolic changes. Eur Respir J. 1998; 12(2): 400–407, doi: 
10.1183/09031936.98.12020400, indexed in Pubmed: 9727792.
38. Luo Y, Zhou L, Li Y, et al. Fat-Free Mass Index for Evaluating 
the Nutritional Status and Disease Severity in COPD. Respir 
Care. 2016; 61(5): 680–688, doi: 10.4187/respcare.04358, in-
dexed in Pubmed: 26814217.
39. Hsieh MJ, Yang TM, Tsai YH. Nutritional supplementation 
in patients with chronic obstructive pulmonary disease. J 
Formos Med Assoc. 2016; 115(8): 595–601, doi: 10.1016/j.
jfma.2015.10.008, indexed in Pubmed: 26822811.
40. Mier A, Brophy C, Wass JA, et al. Reversible respiratory musc-
le weakness in hyperthyroidism. Am Rev Respir Dis. 1989; 
139(2): 529–533, doi: 10.1164/ajrccm/139.2.529, indexed in 
Pubmed: 2913898.
41. El-Yazed HA, El-Bassiony M, Eldaboosy S, et al. Assessment of 
thyroid functions in patients with chronic obstructive pulmo-
nary disease. Egyptian Journal of Chest Diseases and Tuber-
culosis. 2013; 62(3): 387–391, doi: 10.1016/j.ejcdt.2013.07.009.
42. Gow SM, Seth J, Beckett GJ, et al. Thyroid function and en-
docrine abnormalities in elderly patients with severe chronic 
obstructive lung disease. Thorax. 1987; 42(7): 520–525, doi: 
10.1136/thx.42.7.520, indexed in Pubmed: 3125626.
43. Creutzberg EC, Casaburi R. Endocrinological disturbances in 
chronic obstructive pulmonary disease. Eur Respir J. 2003; 22 
(Suppl 46): 76s–80s.
44. Mancini A, Corbo GM, Gaballo A, et al. Relationships between 
plasma CoQ10 levels and thyroid hormones in chronic obs-
tructive pulmonary disease. Biofactors. 2005; 25(1-4): 201–204, 
doi: 10.1002/biof.5520250124, indexed in Pubmed: 16873947.
45. Yasar Z, Kirakli C, Cimen P, et al. Is non-thyroidal illness syn-
drome a predictor for prolonged weaning in intubated chronic 
obstructive pulmonary disease patients? Int J Clin Exp Med. 
2015; 8(6): 10114–10121, doi: 10.4172/2161-105x.s9-e001, in-
dexed in Pubmed: 26309710.
